Biodesix (BDSX) Consolidated Net Income (2019 - 2026)

Biodesix has reported Consolidated Net Income for 8 years, with the latest figure at -$8.2 million in Q1 2026.

• For the quarter ending Q1 2026, Consolidated Net Income rose 24.42% year-over-year to -$8.2 million; the trailing twelve-month figure through Mar 2026 stood at -$32.9 million (up 17.69% YoY), and the FY2025 full-year result was -$35.6 million, up 16.76% from the prior year.
• Consolidated Net Income for Q1 2026 stood at -$8.2 million, down from -$4.0 million in the prior quarter.
• The five-year high for Consolidated Net Income was -$4.0 million in Q4 2025, with the low at -$18.8 million in Q1 2023.
• Historically, Consolidated Net Income has averaged -$11.5 million across 5 years, with a median of -$10.8 million in 2025.
• Annual changes were most pronounced in 2022 — Consolidated Net Income sank 150.21% — and 2025, when it surged 52.08%.
• Biodesix's Consolidated Net Income stood at -$16.4 million in 2022, then soared by 44.05% to -$9.2 million in 2023, then advanced by 8.67% to -$8.4 million in 2024, then surged by 52.08% to -$4.0 million in 2025, then tumbled by 103.13% to -$8.2 million in 2026.
• The last three Consolidated Net Income figures came in at -$8.2 million (Q1 2026), -$4.0 million (Q4 2025), and -$9.1 million (Q3 2025), per Business Quant data.